Age‐related macular degeneration (AMD) is the leading cause of blindness in the elderly
population, and the prevalence of the disease increases exponentially with every decade …

Triamcinolone acetonide (TA) is one of the first pharmacologic compounds evaluated for the
treatment of choroidal neovascularization (CNV) secondary to age-related macular …

PURPOSE: To evaluate the quality of reporting in the neovascular age-related macular
degeneration (nvAMD) literature by applying the Consolidated Standards for Reporting …

Aim: To evaluate the efficacy and safety of triple therapy consisting single-session
photodynamic therapy (PDT), intravitreal bevacizumab (IVB) and intravitreal triamcinolone …

Objective To evaluate the effect of bevacizumab (Avastin; Genentech, Inc, South San
Francisco, California) on inflammation and proliferation in human choroidal …

Purpose The current medical environment demands that quality health care is delivered at
an affordable cost through the use of objective, unbiased clinical data. This study was …

Purpose To investigate the association between the vascular endothelial growth factor
(VEGF) gene and response to either intravitreal bevacizumab (IVB) or photodynamic therapy …

Purpose: We aimed to evaluate the effects of photodynamic therapy (PDT) on different
phenotypes of age-related macular degenerations (AMD): typical AMD (tAMD) and …

The introduction of pharmacotherapy has been one of the most important advances in the
management of retinal disorders. Age-related macular degeneration (AMD) was once …

While angiogenesis is one of the factors associated with the development of CNV due to age-
related macular degeneration (AMD), inflammation and oxidative stress also appear to play …